Skip to Content

Notice

Determination That LIDEX (fluocinonide) Cream and LIDEX-E (fluocinonide) Cream and Nine Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness

Document Details

Information about this document as published in the Federal Register.

Enhanced Content

Relevant information about this document from Regulations.gov provides additional context. This information is not part of the official Federal Register document.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration (FDA) has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Mark Geanacopoulos, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6206, Silver Spring, MD 20993-0002, 301-796-6925.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

In 1984, Congress enacted the Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417) (the 1984 amendments), which authorized the approval of duplicate versions of drug products approved under an ANDA procedure. ANDA sponsors must, with certain exceptions, show that the drug for which they are seeking approval contains the same active ingredient in the same strength and dosage form as the “listed drug,” which is a version of the drug that was previously approved. Sponsors of ANDAs do not have to repeat the extensive clinical testing otherwise necessary to gain approval of a new drug application (NDA).

The 1984 amendments include what is now section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which requires FDA to Start Printed Page 50421publish a list of all approved drugs. FDA publishes this list as part of the “Approved Drug Products With Therapeutic Equivalence Evaluations,” which is generally known as the “Orange Book.” Under FDA regulations, a drug is removed from the list if the Agency withdraws or suspends approval of the drug's NDA or ANDA for reasons of safety or effectiveness, or if FDA determines that the listed drug was withdrawn from sale for reasons of safety or effectiveness (21 CFR 314.162).

Under § 314.161(a) (21 CFR 314.161(a)), the Agency must determine whether a listed drug was withdrawn from sale for reasons of safety or effectiveness: (1) Before an ANDA that refers to that listed drug may be approved; (2) whenever a listed drug is voluntarily withdrawn from sale and ANDAs that refer to the listed drug have been approved; and (3) when a person petitions for such a determination under 21 CFR 10.25(a) and 10.30. Section 314.161(d) provides that if FDA determines that a listed drug was withdrawn from sale for safety or effectiveness reasons, the Agency will initiate proceedings that could result in the withdrawal of approval of the ANDAs that refer to the listed drug.

FDA has become aware that the drug products listed in the table in this document are no longer being marketed.

Application No.DrugApplicant
NDA 016908LIDEX (fluocinonide) Cream; Topical, 0.05%,Medicis Pharmaceutical Corp., 7720 North Dobson Rd., Scottsdale, AZ 85256.
Do.LIDEX-E (fluocinonide) Cream; Topical, 0.05%Do.
NDA 018181MYCELEX (clotrimazole) Solution; Topical, 1%Bayer Health Care, 100 Bayer Rd., Pittsburgh, PA 15205.
NDA 018713MYCELEX (clotrimazole) Lozenge; Oral, 10 milligrans (mg)Do.
NDA 019510PEPCID (famotidine) Injection, 10 mg/milliliter (mL)Merck Research Laboratories, Inc., 770 Sumneytown Pike, West Point, PA 19486.
Do.PEPCID PRESERVATIVE FREE (famotidine) Injection, 10 mg/mLDo.
NDA 020249PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER (famotidine) Injection, 0.4 mg/mLDo.
NDA 021065FEMHRT (ethinyl estradiol; norethindrone acetate) Tablet; Oral, 0.005 mg/1 mgWarner Chilcott LLC, 1 Grand Canal Sq., Docklands, Dublin 2, Ireland.
NDA 050763MITOZYTREX (mitomycin) Injection, 5 mg/vialSuperGen, Inc., 4140 Dublin Blvd., Suite 200, Dublin, CA 94568.
ANDA 086031ISOSORBIDE DINITRATE (isosorbide dinitrate) Tablet; Sublingual, 5 mgWatson Laboratories, 577 Chipeta Way, Salt Lake City, UT 84108.
ANDA 086033ISOSORBIDE DINITRATE (isosorbide dinitrate) Tablet; Sublingual, 2.5 mgDo.

FDA has reviewed its records and, under § 314.161, has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. Accordingly, the Agency will continue to list the drug products listed in this document in the “Discontinued Drug Product List” section of the Orange Book. The “Discontinued Drug Product List” identifies, among other items, drug products that have been discontinued from marketing for reasons other than safety or effectiveness.

Approved ANDAs that refer to the NDAs and ANDAs listed in this document are unaffected by the discontinued marketing of the products subject to those NDAs and ANDAs. Additional ANDAs that refer to these products may also be approved by the Agency if they comply with relevant legal and regulatory requirements. If FDA determines that labeling for these drug products should be revised to meet current standards, the Agency will advise ANDA applicants to submit such labeling.

Start Signature

Dated: August 13, 2013.

Leslie Kux,

Assistant Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 2013-20086 Filed 8-16-13; 8:45 am]

BILLING CODE 4160-01-P